Charles River Laboratories Reports Mixed Q2 Results Amid Vaccine Collaboration
On August 20, Charles River Laboratories (NYSE:CRL) announced a collaboration with Medigen Vaccine Biologics Corp to use next-generation sequencing in MVC's multivalent enterovirus vaccine program. This partnership builds on CRL’s recent acquisition of Pathoquest and reflects the company's efforts to expand its role in biopharmaceutical testing. Despite this strategic move, Charles River reported a mixed second quarter with revenue declining 2.7% year-over-year to $1 billion. The GAAP loss was driven by one-time costs from divesting CDMO and Cell Solutions businesses as well as European Discovery Services sites. Non-GAAP earnings per share fell slightly due to higher study-related costs in the DSA segment. The company raised its non-GAAP guidance for 2026, citing strong performance in digital pathology tools and improved margins in manufacturing operations. However, it cut GAAP EPS guidance as a result of these divestiture losses.
Tickers: $CRL
Topics: biotechnology collaboration next-generation sequencing vaccines